Publication

Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity

Andreasen, S., Bishop, J. A., Hellquist, H., Hunt, J., Kiss, K., Rinaldo, A., Skálová, A., Willems, S. M., Williams, M. & Ferlito, A., Nov-2018, In : Virchows Archiv : an International Journal of Pathology. 473, 5, p. 615-626 12 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • Biphenotypic sinonasal sarcoma

    Final publisher's version, 4 MB, PDF document

    Request copy

DOI

  • Simon Andreasen
  • Justin A Bishop
  • Henrik Hellquist
  • Jennifer Hunt
  • Katalin Kiss
  • Alessandra Rinaldo
  • Alena Skálová
  • Stefan M Willems
  • Michelle Williams
  • Alfio Ferlito

Biphenotypic sinonasal sarcoma (BSNS) is a recently recognized type of sarcoma arising exclusively in the sinonasal tract displaying unique clinical course, histopathology, and genetics. Due to its rarity, only case series and case reports are available. In order to provide an overview of the current understanding of this disease, we present a comprehensive review of the literature and present three previously unreported cases of BSNS. A total of 55 genetically characterized and 41 cases without molecular data were identified in the literature. Two-thirds of patients were female and the peak incidence was in the fifth decade. Fatal outcome was rare (two cases with intracranial extension) and local recurrence occurred in 31.6%, all occurring within 5 years after initial treatment. Histologically, BSNS is highly cellular in the majority of cases and composed of fascicles of spindle cells, with entrapped hyperplastic surface epithelium being a frequent finding. The immunohistochemical profile is characteristic due to the biphasic nature of this lesion, with shared features of both myogenic and neural origin. Rhabdomyoblastic differentiation is apparent in a subset of cases. The most common genetic event is the PAX3-MAML3 fusion (58.6%) but isolated PAX3 rearrangement (19.2%), absence of rearrangements (9.1%), PAX3-FOXO1 (8.1%), PAX3-NCOA1 (4%), and isolated MAML3 rearrangement (2%) have also been reported. In conclusion, the recognition of BSNS is crucial due to its relatively indolent clinical course. A selected immunohistochemical panel and/or molecular confirmation can be used to aid in appropriate diagnosis and consequently in prognostication and to avoid overtreatment with chemotherapy regimens used in its mimics.

Original languageEnglish
Pages (from-to)615-626
Number of pages12
JournalVirchows Archiv : an International Journal of Pathology
Volume473
Issue number5
Publication statusPublished - Nov-2018
Externally publishedYes

    Keywords

  • Adult, Aged, Aged, 80 and over, Biomarkers, Tumor/genetics, DNA-Binding Proteins/genetics, Female, Forkhead Box Protein O1/genetics, Gene Fusion, Gene Rearrangement, Humans, Immunohistochemistry, Male, Middle Aged, Nuclear Proteins/genetics, Nuclear Receptor Coactivator 1/genetics, Oncogene Proteins, Fusion/genetics, PAX3 Transcription Factor/genetics, Paired Box Transcription Factors/genetics, Paranasal Sinus Neoplasms/diagnosis, Phenotype, Prognosis, Sarcoma/diagnosis, Transcription Factors/genetics

ID: 124010338